Dr. Yeo is an academic clinical chemist with over 30 years of experience and is board-certified in Clinical Chemistry (1990) & Toxicological Chemistry (1995) by the American Board of Clinical Chemistry. He was the Director of Clinical Chemistry and Endocrinology Laboratories and Dartmouth Reference Laboratory and Professor of Pathology at Dartmouth-Hitchcock Medical Center(1995-2007). Prior to that he was the Scientific Director of Clinical Chemistry and Endocrinology Laboratories and an Assistant Professor at Beth Israel Hospital and Harvard Medical School (1987-1995). Dr. Yeo was past-President of the Commission on Accreditation in Clinical Chemistry (2017-2018), past-Chair of the AACC Personalized Medicine Division (2017-2018), past Treasurer of the AACC Proteomics & Metabolomics Division (2015-2016), past-Chair of Chicago Section of AACC (2014-2015), past-Chair of the AACC Molecular Pathology Division (2008-2010), and past Vice-President of American Board of Clinical Chemistry (2003-2005). His research interests are in emerging angiogenic biomarkers, clinical mass spectrometry and clinical pharmacogenomics applications for precision medicine. He had published more than 100 original articles, book chapters and abstracts in the field of clinical chemistry and pharmacogenomics.
University of Washington
Seattle, WA
Senior Postdoc Fellow - Clinical Chemistry
1987
Howard University Cancer Center
Washington, DC
Research Associate - Cancer research
1985
SUNY Downstate Medical Center
Brooklyn, NY
PhD - Biochemistry
1983
University of Malaya
Kuala Lumpur, Malaysia
BSc - Biochemistry
1977
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen.
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.
PMID: 37639675
Is the automated Elecsys tacrolimus assay on the Roche cobas e 602 analyzer an acceptable replacement for a liquid chromatography-tandem mass spectrometry-based assay?
Is the automated Elecsys tacrolimus assay on the Roche cobas e 602 analyzer an acceptable replacement for a liquid chromatography-tandem mass spectrometry-based assay? Am J Clin Pathol. 2024 Jan 04; 161(1):97-106.
PMID: 37724434
Implementation of pharmacogenomics testing for precision medicine.
Implementation of pharmacogenomics testing for precision medicine. Crit Rev Clin Lab Sci. 2024 Mar; 61(2):89-106.
PMID: 37776898
Is the automated Elecsys tacrolimus assay on the Roche cobas e 602 analyzer an acceptable replacement for a liquid chromatography-tandem mass spectrometry-based assay?
Is the automated Elecsys tacrolimus assay on the Roche cobas e 602 analyzer an acceptable replacement for a liquid chromatography-tandem mass spectrometry-based assay? Am J Clin Pathol. 2023 Sep 19.
PMID: 37724434
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen.
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2023 Aug 28.
PMID: 37639675
Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]).
Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]). Am J Nephrol. 2023; 54(7-8):281-290.
PMID: 37356428
Reducing Specimen Rejection Rates Using Concentration-Dependent Hemolysis Rejection Thresholds.
Reducing Specimen Rejection Rates Using Concentration-Dependent Hemolysis Rejection Thresholds. J Appl Lab Med. 2023 03 06; 8(2):285-295.
PMID: 36592084
Use of a Vanadate Oxidation Conjugated Bilirubin Assay to Reduce Test Cancellations Resulting from Hemolyzed Specimens in Pediatric Patients.
Use of a Vanadate Oxidation Conjugated Bilirubin Assay to Reduce Test Cancellations Resulting from Hemolyzed Specimens in Pediatric Patients. Am J Clin Pathol. 2023 01 04; 159(1):6-9.
PMID: 36413387
Biotin Interference in Immunoassays and Patient Safety.
Biotin Interference in Immunoassays and Patient Safety. Am J Clin Pathol. 2023 01 04; 159(1):1-2.
PMID: 36409746
Implementation of pharmacogenomics into inpatient general medicine.
Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
PMID: 36729768
NACCCA Lifetime Distinguished Contribution in Education Award
North American Chinese Clinical Chemists Association (NACCCA) Board
2023
President
Commission on Accreditation in Clinical Chemistry
2017 - 2018
Chair, Personalized Medicine Division
American Association for Clinical Chemistry
2017 - 2018
Albert A. Dietz Service Award
Chicago Section of AACC
2016
Chair, Chicago Section
American Association for Clinical Chemistry
2014
Samuel Natelson Research Award
Chicago Section of American Association for Clinical Chemistry
2013
AACC Outstanding Speaker Award
American Association for Clinical Chemistry
2013
International Travel Fellowship
American Association for Clinical Chemistry
2005
Vice-President
American Board of Clinical Chemistry
2003 - 2005
Fellow
National Academy of Clinical Biochemistry
1997
Diplomate
American Board of Clinical Chemistry
1990